Header Logo

Connection

Ekihiro Seki to Liver Neoplasms

Back to Details
This is a "connection" page, showing publications Ekihiro Seki has written about Liver Neoplasms.
Ekihiro Seki
Connection Strength
10.104
Liver Neoplasms
  1. Metastatic tumor growth in steatotic liver is promoted by HAS2-mediated fibrotic tumor microenvironment. J Clin Invest. 2025 Feb 13; 135(7).
    View in: PubMed
    Score: 0.894
  2. Unveiling the cancer risk nexus of the steatotic liver. Trends Endocrinol Metab. 2024 Aug; 35(8):708-719.
    View in: PubMed
    Score: 0.841
  3. In?Vivo and In?Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations. Cell Mol Gastroenterol Hepatol. 2023; 16(3):355-367.
    View in: PubMed
    Score: 0.794
  4. Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment. Cell Metab. 2023 07 11; 35(7):1209-1226.e13.
    View in: PubMed
    Score: 0.791
  5. Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis. Semin Liver Dis. 2020 Aug; 40(3):307-320.
    View in: PubMed
    Score: 0.638
  6. NOD-like receptor C4 Inflammasome Regulates the Growth of Colon Cancer Liver Metastasis in NAFLD. Hepatology. 2019 11; 70(5):1582-1599.
    View in: PubMed
    Score: 0.601
  7. Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets. Semin Liver Dis. 2019 02; 39(1):26-42.
    View in: PubMed
    Score: 0.587
  8. The contribution of toll-like receptor signaling to the development of liver fibrosis and cancer in hepatocyte-specific TAK1-deleted mice. Int J Cancer. 2018 01 01; 142(1):81-91.
    View in: PubMed
    Score: 0.536
  9. Finding a new role for NEMO: A key player in preventing hepatocyte apoptosis and liver tumorigenesis by inhibiting RIPK1. Hepatology. 2016 07; 64(1):295-7.
    View in: PubMed
    Score: 0.489
  10. Exosome Migration Inhibitory Factor as a Marker and Therapeutic Target for Pancreatic Cancer. Gastroenterology. 2016 Apr; 150(4):1033-5.
    View in: PubMed
    Score: 0.480
  11. Microbiome-obesity-liver cancer interaction: senescence of hepatic stellate cells and bile acids play new roles. Gastroenterology. 2014 Mar; 146(3):860-1.
    View in: PubMed
    Score: 0.416
  12. TAK1 regulates hepatic cell survival and carcinogenesis. J Gastroenterol. 2014 Feb; 49(2):185-94.
    View in: PubMed
    Score: 0.415
  13. Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J Gastroenterol Hepatol. 2013 Aug; 28 Suppl 1:38-42.
    View in: PubMed
    Score: 0.402
  14. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc Natl Acad Sci U S A. 2010 Jan 12; 107(2):844-9.
    View in: PubMed
    Score: 0.313
  15. Hepatic prohibitin 1 and methionine adenosyltransferase a1 defend against primary and secondary liver cancer metastasis. J Hepatol. 2024 Mar; 80(3):443-453.
    View in: PubMed
    Score: 0.206
  16. Deregulated 14-3-3? and methionine adenosyltransferase a1 interplay promotes liver cancer tumorigenesis in mice and humans. Oncogene. 2021 09; 40(39):5866-5879.
    View in: PubMed
    Score: 0.175
  17. Reciprocal Regulation Between Forkhead Box M1/NF-?B and Methionine Adenosyltransferase 1A Drives Liver Cancer. Hepatology. 2020 11; 72(5):1682-1700.
    View in: PubMed
    Score: 0.165
  18. The mitochondrial chaperone Prohibitin 1 negatively regulates interleukin-8 in human liver cancers. J Biol Chem. 2019 02 08; 294(6):1984-1996.
    View in: PubMed
    Score: 0.146
  19. Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2018 10 16; 115(42):E9879-E9888.
    View in: PubMed
    Score: 0.144
  20. Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. Cancer Cell. 2018 06 11; 33(6):1061-1077.e6.
    View in: PubMed
    Score: 0.141
  21. Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer. Gastroenterology. 2018 08; 155(2):557-571.e14.
    View in: PubMed
    Score: 0.140
  22. p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells. Cancer Cell. 2016 06 13; 29(6):935-948.
    View in: PubMed
    Score: 0.122
  23. NCOA5, IL-6, type 2 diabetes, and HCC: The deadly quartet. Cell Metab. 2014 Jan 07; 19(1):6-7.
    View in: PubMed
    Score: 0.104
  24. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell. 2013 Oct 10; 155(2):384-96.
    View in: PubMed
    Score: 0.102
  25. Transforming growth factor-? signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1. Gastroenterology. 2013 May; 144(5):1042-1054.e4.
    View in: PubMed
    Score: 0.097
  26. p38a inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species. Cancer Res. 2013 Jan 01; 73(1):215-24.
    View in: PubMed
    Score: 0.096
  27. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology. 2012 Aug; 143(2):307-20.
    View in: PubMed
    Score: 0.093
  28. Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice. J Hepatol. 2006 Nov; 45(5):688-95.
    View in: PubMed
    Score: 0.061
  29. Repeated hepatocyte injury promotes hepatic tumorigenesis in hepatitis C virus transgenic mice. Cancer Sci. 2003 Aug; 94(8):679-85.
    View in: PubMed
    Score: 0.050
  30. Metastatic gastrinoma to the liver 20 years after primary resection. J Gastroenterol. 2000; 35(9):717-20.
    View in: PubMed
    Score: 0.039
  31. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab. 2014 Jul 01; 20(1):133-44.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.